Arecor Therapeutics plc
(“Arecor” or the “Company”)

ARECOR ESTABLISHES PARTNERSHIP WITH BIOPHARMACEUTICAL COMPANY TO DEVELOP NOVEL FORMULATION OF PEPTIDE THERAPY

- Partner to fund development work with option to acquire rights to proprietary formulation under Arecor’s technology licensing model

Cambridge, UK, 12 March 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces a formulation development collaboration with a clinical-stage biopharmaceutical company developing peptide therapies. The partnership aims to develop a differentiated formulation of the partner’s peptide therapy using Arecor’s proprietary formulation technology platform, Arestat™. The collaboration reinforces Arecor’s expertise developing novel formulations of peptide therapeutics.

Under the terms of the agreement, the partner will fund Arecor’s development activities with the option to license rights to the new proprietary formulation and associated intellectual property to further develop and commercialise the product.

Arecor has an excellent track record developing challenging therapeutic peptide product profiles using its Arestat™ technology. Within the Company’s broader product portfolio, Arecor continues to progress the potential of its Arestat™ platform to enable oral peptide delivery, through its initial oral glucagon-like peptide-1 (GLP-1) receptor agonist programme.

The global peptide therapeutics market is projected to reach more than $100 billion by 2034 growing at a CAGR of 10.8% 1, driven by peptide therapeutics’ strong efficacy and selectivity towards different receptors on target cells, the rise of endocrine and metabolic diseases, and technological advancements in the field.

Sarah Howell, Chief Executive Officer of Arecor, said: “Peptides are an increasingly important class of therapeutics to treat a wide range of chronic conditions. Arecor has significant expertise in developing novel formulations of therapeutic peptides to address unmet patient needs in this large and growing market. This collaboration further validates our leadership in this field.”

-ENDS-

References
1. Future Market Insights: Peptide Therapeutics Market Outlook from 2024 to 2034

For more information, please contact:

Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com

David Ellam, Interim Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com

Singer Capital Markets Advisory LLP (NOMAD and Joint Broker)
Phil Davies, Sam Butcher Tel: +44 (0) 20 7496 3000

WG Partners LLP (Joint Broker)
Nigel Barnes, Satheesh Nadarajah
David Wilson, Claes Spang Tel: +44 (0) 20 3705 9321

ICR Healthcare
Chris Gardner, David Daley, Lindsey Neville Tel: +44 (0) 20 3709 5700
Email: arecor@icrhealthcare.com

Notes to Editors

About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com